IL1A and COVID-19: The “SAVE-MORE” study evaluated the safety and efficacy of Anakinra, an IL-1α/β inhibitor, in a large cohort of COVID-19 patients at risk of progression to respiratory failure, with a level of suPAR ≥ 6 ng/mL.